Grupo Fleury

What Grupo Fleury does

Grupo Fleury S.A. (B3: FLRY3) is a Brazilian integrated diagnostic medicine platform founded in 1926, operating 585 physical diagnostic units across 13 Brazilian states under 55 brands, with 23,000+ employees and 4,600+ physicians. The company processes approximately 368 million exams per year and runs four complementary revenue channels: B2C diagnostic services through branded units and the free Saúde iD discount card; B2B Lab-to-Lab Pardini serving 7,800+ partner laboratories across 2,200+ municipalities via 8,000+ collection points and 126,000 km/day logistics; B2B hospital diagnostic outsourcing through Grupo Fleury Diagnósticos para Hospitais; and B2B corporate health management through the Saúde Digital platform covering 4M+ beneficiaries across enterprise clients.

The technology stack combines a unified electronic health record spanning all 55 brands, the MyPardini digital platform for lab-to-lab partners, the Saúde Digital corporate health platform (telemedicine, primary care, occupational health, mental health), specialty capabilities in genomics (Genesis Genomics with 300+ tests, Sommos genetic testing), toxicology (Toxicologia Pardini serving 14,500+ labs with keratin-based analysis), and clinical research infrastructure. Specialized clinical lines include infusion therapy, fertility, oncology (Progenetica), orthopedics (Vita), ophthalmology, and cryopreservation (Criovida), with a new B2B marketplace (Pardis) for medical supplies.

The business model combines reimbursement-based B2C diagnostic services, per-test transaction fees from B2B Lab-to-Lab partners, subscription/PEPM-based corporate health contracts, and marketplace commissions. FY2025 revenue reached R$9.003 billion (+8.2% YoY), with Q1 2026 revenue of R$2.4 billion (+10.1% YoY), EBITDA margin of 27.3%, and ROIC of 17.0%. Capital structure is conservative at 1.0x net debt/EBITDA, supported by a Moody's AAA.br stable rating, and the company is preparing a potential Nasdaq ADR listing while continuing its serial acquisition strategy (21 deals since 2017).

Name

Grupo Fleury

Legal name

Grupo Fleury S.A.

Website

https://grupofleury.com.br

Company type

Public

Founded year

1926

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Grupo Fleury is a Brazilian integrated diagnostic medicine platform operating 585 units across 13 states under 55 brands, serving B2C patients, 7,800+ partner laboratories via Lab-to-Lab Pardini, hospitals, and corporate clients through the Saúde Digital platform.

Ownership category

akta.pro rank

Product category

Diagnostic Medicine

NAICS

Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Professional, Scientific, and Technical Services (541)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Diagnostic medicine
• Clinical laboratory testing
• Medical imaging services
• Corporate health solutions
• Genetic testing

Headquarters

HQ city

Jabaquara

HQ country

Brazil

HQ region

Latin America

Offices8 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. B2C Diagnostic Services: Revenue from diagnostic medicine services (clinical analysis, imaging, vaccines, specialty care) delivered through 585 physical units to individual consumers and health insurance beneficiaries. Services are paid through health insurance reimbursement or direct out-of-pocket payment, supported by the free Saúde iD discount card (up to 80% discount for uninsured patients).
2. B2B Laboratory Services (Lab-to-Lab): Lab-to-Lab Pardini provides diagnostic testing services to 7,800+ partner laboratories nationwide via a network of 126,000 km/day logistics and 8,000 collection points. Revenue is generated through test processing fees billed to partner labs on a per-test or contractual basis.
3. Corporate Health Solutions (Saúde Digital): Enterprise health management solutions sold to corporate clients including primary care coordination, 24/7 teleconsultation, telehealth specialties, occupational health, and mental health services. Billed through annual or multi-year corporate contracts based on headcount or per-employee-per-month (PEPM) models.
4. Hospital Diagnostic Partnerships: Integrated diagnostic services contracted to hospitals and clinics including clinical analyses, imaging, and decision support, with flexible models adapting to each institution's operational needs.
5. Pardis Marketplace: B2B digital marketplace connecting healthcare suppliers (pharmaceuticals, medical supplies) with laboratories, clinics, and hospitals, generating revenue through transaction fees and distribution services.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Grupo Fleury is a Brazilian diagnostic medicine company operating 585 physical units across Brazil under 55 brands, performing 368 million exams per year. It provides clinical laboratory testing, diagnostic imaging, vaccines, genetic testing, and specialty care to individual consumers through B2C units, to hospitals and partner laboratories through B2B Lab-to-Lab services, and to corporate clients through the Saúde Digital health platform and Pardis B2B marketplace.

Product overview

Grupo Fleury is a leading Brazilian healthcare diagnostics company operating through a platform-plus-modules architecture. The core offerings include diagnostic medicine services (B2C units and mobile care), B2B laboratory services (lab-to-lab partnerships and hospital diagnostics), digital health platforms (Saúde Digital, MyPardini, Pardis marketplace), and specialty clinics (infusion centers, orthopedics, ophthalmology, reproductive medicine, oncology). The company manages 55 brands including flagship Fleury, acquired brands (Hemolab, São Lucas Rio Claro, Bioclínico), and specialized subsidiaries (Genesis Genomics, Fleury Genômica, Progenetica, Weinmann, Hermes Pardini, Labs a+, and many regional laboratories). The ecosystem is structured around four growth avenues: B2C Diagnostic Medicine, B2B Diagnostic Medicine, New Links (specialty clinics), and Health Platforms (digital integration). In 2026, the company celebrated its centennial with the launch of 'Fleury Marco 100' premium units and the Fleury Life Care wellness initiative.

Differentiator

Problem solved

Functional benefit

Brands

• 55 marcas (55 brands): Comprehensive portfolio of diagnostic medicine brands including clinical analysis, imaging, vaccines, genetics, and digital health platforms across Brazil
• Fleury Marco 100
• Fleury Life Care

Quantifiable outcome

• 17% reduction in health insurance claims in corporate clients using Saúde Digital's primary care program (12-month post vs. pre-implementation comparison)
• +8 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Laboratório São Lucas (Rio Claro)coreStrategic or Co-development Partner · 1 October 2025Acquisition of Laboratório São Lucas in Rio Claro, São Paulo for R$34 million, adding 3 units. This is Fleury's 21st acquisition since 2017, strengthening its presence in a fast-growing region with significant socioeconomic growth. The lab has operated since 1992 and is ONA-certified.
• Laboratório São Lucas (Rio Claro)coreStrategic or Co-development Partner · 1 October 2025São Lucas was the 21st acquisition since 2017, adding 3 diagnostic units in Rio Claro, São Paulo to Grupo Fleury's network of 585 units. The lab's ONA certification and regional reputation for quality diagnostics were key factors in the acquisition.
• Hemolab Medicina LaboratorialcoreStrategic or Co-development Partner · 1 June 2025Acquisition of Hemolab Medicina Laboratorial in Conselheiro Lafaiete, Minas Gerais for R$39.5 million. Hemolab had R$31 million in revenue last year, with the deal valued at a 4.7x EBITDA multiple. Hemolab operates 15 units across 9 municipalities and was founded over 27 years ago. The acquisition strengthens Fleury's presence in Minas Gerais.
• Grupo Pardini (Business Combination)coreStrategic or Co-development Partner · 1 April 2023The combination of business with Grupo Pardini was concluded in April 2023, adding the Lab-to-Lab Pardini network (7,800+ partner labs, 120M+ exams/year), Hermes Pardini (70+ units), MyPardini digital platform, Toxicologia Pardini, and other Pardini brands to the Group Fleury portfolio. Since 2017, 11 acquisitions in diagnostic medicine have been completed.
• Independent Trust Channel OperatorminorOthersGrupo Fleury's Canal de Confiança (Trust Channel) is operated by an independent company, ensuring total security, confidentiality, and anonymity for whistleblowers. Available 24/7, 365 days per year, via telephone (0800-601-6943) and website (contatoseguro.com.br/pt/grupofleury). Applicable to all 55 brands of the Group.

Scale indicators21 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat6 records

Customer concentration

• LinkedInlinkedin.com/company/grupo-fleury

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries27 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grupo Fleury